Coverage Guide · Updated April 28, 2026
Does Medicare Cover Wegovy? (2026 Coverage Guide)
Covered for cardiovascular indication only for Medicare members in 2026. Wegovy is FDA-approved for chronic weight management. Coverage depends on your specific plan, employer benefits, and prior authorization rules.
1. Medicare coverage status for Wegovy
| Detail | Status |
|---|---|
| Plan type | Federal |
| Coverage status | Covered for cardiovascular indication only |
| FDA indication | chronic weight management |
| List price | $1349/mo (cash-pay retail) |
| Manufacturer direct | NovoCare cash-pay, about $499/mo |
| Appeal success rate | ~15% when denied |
2. Medicare's coverage rules
Medicare Part D historically did not cover GLP-1s for weight loss. After the 2024 SELECT trial expanded the Wegovy label to include cardiovascular risk reduction, some Part D plans now cover Wegovy for patients with established cardiovascular disease and overweight/obesity. Medicare still does not cover GLP-1s for weight loss alone.
3. Prior authorization requirements
Most Medicare plans require:
- BMI 30+ (or 27+ with at least one comorbidity such as type 2 diabetes, hypertension, sleep apnea, or non-alcoholic fatty liver disease)
- Documented prior weight-loss attempts (often 6 months of supervised diet and exercise)
- No contraindications (medullary thyroid carcinoma history, MEN-2)
- Some plans require step therapy through a cheaper drug first (often phentermine or metformin)
Prior auth approval typically takes 3 to 14 days. Some prescribers offer PA submission as part of the visit, which speeds the process.
4. If denied: how to appeal
Medicare appeals succeed about 15% of the time when prepared properly. Steps:
- Request the formal denial letter (your right under federal law). It will list the specific reason for denial.
- Have your prescriber write a letter of medical necessity. Should document BMI, comorbidities, prior weight-loss attempts, contraindications to cheaper alternatives, and any cardiovascular risk factors.
- Submit the appeal within the deadline (usually 30 to 180 days depending on plan).
- If denied at first appeal, escalate to second-level review or external review.
5. If uncovered: cheapest alternatives for Medicare members
- NovoCare cash-pay: about $499/mo. Direct from the manufacturer, no insurance required.
- Manufacturer savings card: as low as $25/mo for eligible commercial-insurance patients. Does not apply to Medicare plans.
- Compounded semaglutide: $80 to $349/mo for compounded semaglutide, $132 to $600/mo for compounded tirzepatide. Cash-pay only.
- Switch to the diabetes-indicated version (Mounjaro or Ozempic) if you have type 2 diabetes, which has higher coverage rates.
FAQ
Does Medicare cover Wegovy in 2026?
Covered for cardiovascular indication only for Medicare members. Wegovy is FDA-approved for chronic weight management. Coverage depends on your specific plan, employer benefits (for commercial plans), and prior authorization requirements. Medicare Part D historically did not cover GLP-1s for weight loss. After the 2024 SELECT trial expanded the Wegovy label to include cardiovascular risk reduction, some Part D plans now cover Wegovy for patients with established cardiovascular disease and overweight/obesity. Medicare still does not cover GLP-1s for weight loss alone.
What is the prior authorization process for Wegovy on Medicare?
Most Medicare plans require: BMI 30+ (or 27+ with comorbidity), documented prior weight-loss attempts (often 6 months), no contraindications, and sometimes step therapy through cheaper drugs first. Approval usually takes 3 to 14 days.
If Medicare denies Wegovy, can I appeal?
Yes. Medicare appeal success rate for GLP-1 denials is approximately 15%. Strongest appeals document BMI, comorbidities (diabetes, hypertension, sleep apnea, NAFLD), prior weight-loss attempts, and any contraindications to alternative drugs.
If insurance won't cover Wegovy, what is the cheapest alternative?
Three options. First, NovoCare cash-pay from the manufacturer at about $499/mo. Second, the manufacturer savings card if you have commercial insurance ($25/mo for eligible patients). Third, compounded semaglutide from a licensed compounding pharmacy ($80 to $349/mo for compounded semaglutide, $132 to $600/mo for compounded tirzepatide).